Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1

Status

Completed 12Recruiting 11Active not recruiting 5Terminated 3Withdrawn 2Unknown 1No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 33Genitourinary 18Breast 18Gastrointestinal 17Dermatologic 9Lymphoid 8Other solid neoplasm 7Head & Neck 4Tumor-Agnostic 3Other hematologic neoplasm 3Gynecologic 3Plasma cell 2CNS 2Sarcoma 1

Conditions

Neoplasms 3

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × atezolizumab × Tumor-Agnostic × Clear all
NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Terminated
33 enrolled
Tumor-Agnostic

Neoplasms

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Sanofi

Phase 1/2 Terminated
107 enrolled 30 charts
Tumor-Agnostic

Neoplasms

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡